Drug intelligence / Profile preview

zoligratinib + fulvestrant

Development stage: Unknown
Lead developer: Debiopharm
Modality: Small Molecules
Administration: Oral, Intramuscular

Overview

A combination therapy consisting of zoligratinib (DEBIO 1347), an oral selective FGFR1-3 inhibitor, and fulvestrant, a selective estrogen receptor downregulator (SERD). This combination is being investigated for the treatment of estrogen receptor-positive (ER+), HER2-negative metastatic breast cancer with FGFR gene amplifications. The combination aims to target both the estrogen receptor pathway and the FGFR signaling pathway, which may be involved in endocrine resistance mechanisms.

Targets

ESR1 (ERα)FGFR3 (Fibroblast growth factor receptor 3)ESR2 (ERβ)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)

Beyond the preview

Go deeper on zoligratinib + fulvestrant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zoligratinib + fulvestrant.

Explore the full profile